

INFORMATION DISCLOSURE CITATION

Atty. Docket No.: 02481.1669-00000	
Applicants: Anuschirwan PEYMAN et al.	Serial No.: To be assigned 09/554267
Filing Date: May 12, 2000	Group Art Unit: To be assigned

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date	Name	Class	Sub Class	Filing Date (if appropriate)

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Sub Class	Translation Yes or No
<i>J3</i>	1	DE 195 02 912 A1	1AUG96	Germany		<i>No</i>
<i>J3</i>	2	WO 94/21664	29SEP94	WIPO		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

<i>J3</i>	3	Woolf, T.M., et al., "Specificity of antisense oligonucleotides <i>in vivo</i> ," Proc. Natl. Acad. Sci., USA, Vol. 89, pp. 7305-7309 (1992)
	4	Peyman, A., et al., "Minimally modified oligonucleotides - combination of end-capping and pyrimidine-protection," Biol. Chem. Hoppe-Seyler, Vol. 377, pp. 67-70 (1996)
	5	Le Poole, I.C., et al., "Tenascin is overexpressed in vitiligo lesional skin and inhibits melanocyte adhesion," British Journal of Dermatology, Vol. 137, No. 2, pp. 171-178 (1997)
	6	O'Donnell, D.B., et al., "Tenascin is abundant in the skin of vitiligo patients," J. Invest. Dermatol., Vol. 98, No. 4, p. 620, Abstract 409 (1992)
	7	Torrence, P.F., et al., "Targeting RNA for degradation with a (2'-5')oligoadenylate-antisense chimera," Proc. Natl. Acad. Sci., USA, Vol. 90, pp. 1300-1304 (1993)
	8	Ortigao, J.F.R., et al., "Antisense effect of oligodeoxynucleotides with inverted terminal internucleotidic linkages: a minimal modification protecting against nucleotide degradation," Antisense Research and Dev., Vol. 2, pp. 129-146 (1992)

Examiner: <i>[Signature]</i>	Date Considered: <i>3/28/01</i>
* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO-1449 Patent and Trademark Office - U.S. Department of Commerce	